ftfFT,cTef, WrdWlcS

, f^T-492015 (W^-%ef:office.mdnrhmi@gmail.com

. / 2015 / . 04/2015

flfcT,

1.2. RiRld

RHdl

SrWcTTeT

(Second Trimester) 3 Deworming

D.O. No.M. 12015/271/2014-MCH, Dated 19th Feb, 2015

===00===(STH)

t

1 1 (Jl"ldl<t>K c

vjft

^ Pi l i f ( 5%76% cT^ t

ftr?J

50%

TTST f

3Rf eFT

SJT^TcT

fel iff ^PlPl-MI

t fc|5j)fcicb>{nf^disft cfr fen?

fetch TT^§ (IF A) cf?T J|lfdi|| f^y>d

3T^faTcT ^H^ddl f^fef

Piii' ui^TT t,

" TT t,

Helminthiasis c

viMilVl ^^Id

Abnormalities M 6 I 6101

dH ^ Preventive Chemotherapy in Human

f^TT t % Mebendazole or Albendazole ^T

cf?f Congenital

yJ-TTfcTcT fftof All pregnant women in

STH endemic areas (Prevalence more than 20%)i

D e w o r m i n g g u i d e l i n e ( P a g e 1 j 3 )

3,2 for

i* .0••.

be none a*,,; 1st t rime

_f pregnancypreferably {luringthe 2nd trimeter}

Albendazole cf> feHJ

(Second Trimester) Albendazole 400mg IP^TRT

Albendazole cp Specific ^cy^N ^TT Side effect t %

STRT, *te TJcf fctof ^ft '{-H'WI Ft ^cj^cl) ^Cases

(1st trimester) ^f eTFU

STF fct TJcf ^U

(Second Trimester)

l3Tf 10

TlTcft dNHM ^ (l5 30 f%tft . ".) f^TT ^TT ^T^cTT t

^T Rb<Ml-c|<M-l

STTrTT t I f^R

^R f^TT

t TTR

Trimester) ^ 7FRT cf>i 40dl

(Second

fef^

D e w o r m i n g g u i d e l i n e ( P a g e 2 | 3)

Antihelminthic

cfSTT

t I >ET%

Ff^t

Antihelminthic

^ feHJ

Weft3T^

tft

HTdT

cTft ^

RnTc

Antihelminthic

^TFTT

3Kl4cl

t if^ffe f^TT ^TFTT t I

infer

Antihelminthic^ ^lP)fcRJl qfl"

(Tab. Albendazole 400 mg) DOT Administration

Compliance Monitor

Mlel-l ^fT vjTFTT cf^TT i el <s| cfft

-'— National Guidelines for Deworming in Pregnancy (Page - 21)

R HI'* 4</ 04 72015

1. irg^ ^ i c i , U.TT. -?TRFT,^HTaf ^RcT I

2. STRJcfrT, " [R-ezf TTcf TTRqT? cbe^|U| fct^TFT,

3.4.5.

6.

, ^PTT

y»oll>HJlci

D e w o r m i n 3 1 3 )